Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window

The company licenses U.S. and Canadian rights to Phase II plasminogen activator, derived from vampire bat saliva, from German firm PAION GmbH; desmoteplase is Forest’s first biologic product. The companies expect to initiate the rolling BLA submission as early as 2007.